Buying Opportunity or Terrible News: Tetraphase Pharmaceuticals Due Diligence - Brokerbank Securities

Sep 10, 2015, 08:55 ET from BrokerBank Securities, Inc.

NEW YORK, Sept. 10, 2015 /PRNewswire/ -- PRNewswire - Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin.

For the U.S. Food and Drug Administration (FDA), the primary analysis evaluated the responder outcome (a combination of clinical cure rate and microbiological response) in the Microbiological Intent-to-Treat (micro-ITT) population at the Post-Treatment (PT) visit (defined as 6-8 days after the completion of therapy) using a 10% non-inferiority margin. For the European Medicines Agency (EMA), the primary analysis evaluated the microbiological response in the microbiologically modified ITT (micro-MITT) population and microbiologically evaluable (ME) populations at the PT visit using a 10% non-inferiority margin. Eravacycline did not achieve the primary endpoint under either analysis.

This has been a certain setback for the company and its shares, however, there may exist an opportunity hidden behind the negative publicity.

For a more detailed research report with analyst comments and recommendation on Tetraphase Pharmaceutical, Inc. please follow the link. There is no cost obligation required to view analyst brief:

Copy and paste to browser may be required.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, a broad-spectrum intravenous and oral antibiotic that is being evaluated in phase 3 clinical trials, and two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit for more company information.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.  

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source.  A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.


SOURCE BrokerBank Securities, Inc.